Literature DB >> 7298871

Effects of moderate and high doses of marihuana on thermal pain: a sensory decision theory analysis.

W C Clark, M N Janal, P Zeidenberg, G G Nahas.   

Abstract

Sixteen habitual marihuana users, selected for their good mental and physical health, were hospitalized for three months in the New York State Psychiatric Institute. During the first month, the subjects were drug free; during the second month, they smoked marihuana cigarettes provided by NIDA (2% THC, 20 mg per cigarette) at the rate of 3 to 12 a day. A modified Hardy-Wolff dolorimeter was used to present 20 thermal stimuli of 30-second duration in a random manner at nine different intensities. Subjects responded from a 14-category scale, and data were analyzed according to sensory decision theory analysis. During the third month, the subjects were again drug free. At the noxious thermal intensities, there was a decrease in the pain report criterion during the first two weeks of smoking. The pain enhancement effect was followed by return to the presmoking pain level during weeks 3 and 4 and in the postsmoking period, indicating that tolerance had developed. There was also an increase in pain discriminability during the four weeks of smoking which extended for one week after smoking. Tolerance developed to the pain report criterion but not to the thermal discriminability. This study suggests that marihuana may have hyperalgesic activity and probably enhances the perception of pain, in moderate smokers. In contrast, heavy smoking had little effect on discriminability and caused an increase in the pain report criterion.

Entities:  

Mesh:

Year:  1981        PMID: 7298871     DOI: 10.1002/j.1552-4604.1981.tb02608.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  11 in total

Review 1.  Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.

Authors:  F A Campbell; M R Tramèr; D Carroll; D J Reynolds; R A Moore; H J McQuay
Journal:  BMJ       Date:  2001-07-07

2.  A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain.

Authors:  Barth Wilsey; Thomas Marcotte; Alexander Tsodikov; Jeanna Millman; Heather Bentley; Ben Gouaux; Scott Fishman
Journal:  J Pain       Date:  2008-04-10       Impact factor: 5.820

3.  Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.

Authors:  Caitlin M Nealon; Angela N Henderson-Redmond; David E Hale; Daniel J Morgan
Journal:  Neuropharmacology       Date:  2019-01-08       Impact factor: 5.250

4.  Cannabis and endocannabinoid modulators: Therapeutic promises and challenges.

Authors:  Igor Grant; B Rael Cahn
Journal:  Clin Neurosci Res       Date:  2005

5.  Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy.

Authors:  Mark S Wallace; Thomas D Marcotte; Anya Umlauf; Ben Gouaux; Joseph H Atkinson
Journal:  J Pain       Date:  2015-04-03       Impact factor: 5.820

Review 6.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

7.  The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids.

Authors:  Michelle Sexton; Jose M Garcia; Aminah Jatoi; Carey S Clark; Mark S Wallace
Journal:  J Natl Cancer Inst Monogr       Date:  2021-11-28

8.  Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.

Authors:  J Manzanares; Md Julian; A Carrascosa
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

Review 9.  [Cannabis and cannabinoids for the treatment of acute and chronic pain].

Authors:  Michael Schäfer; Sascha Tafelski
Journal:  Anaesthesist       Date:  2021-07-01       Impact factor: 1.041

10.  Cannabinoid 1 receptor knockout mice display cold allodynia, but enhanced recovery from spared-nerve injury-induced mechanical hypersensitivity.

Authors:  Alexandra Sideris; Boris Piskoun; Lori Russo; Monica Norcini; Thomas Blanck; Esperanza Recio-Pinto
Journal:  Mol Pain       Date:  2016-05-20       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.